BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37689651)

  • 21. Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Liver Metastases from Colorectal Cancer: a Multicenter, Propensity Score-Matched Cohort Study.
    Hirokawa F; Ueno M; Nakai T; Kaibori M; Nomi T; Iida H; Tanaka S; Komeda K; Hayami S; Kosaka H; Hokuto D; Kubo S; Uchiyama K
    J Gastrointest Surg; 2022 Apr; 26(4):772-781. PubMed ID: 34664190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparison of follow-up treatment regimens for colorectal cancer liver metastases without objective response to neoadjuvant chemotherapy: direct surgery or surgery after second-line chemotherapy].
    Lyu XY; Bi XY; Zhao H; Chen QC; Luo ZW; Zhang BL; Zhang XS; Cai JQ
    Zhonghua Wai Ke Za Zhi; 2022 May; 60(5):454-460. PubMed ID: 35359087
    [No Abstract]   [Full Text] [Related]  

  • 23. 2-4 weeks is the optimal time to operate on colorectal liver metastasis after neoadjuvant chemotherapy.
    Huang Y; Jiang H; Xu L; Wu X; Wu J; Zhang Y
    Biosci Trends; 2023 May; 17(2):160-167. PubMed ID: 37088556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?
    Pan Z; Peng J; Lin J; Chen G; Wu X; Lu Z; Deng Y; Zhao Y; Sui Q; Wan D
    Cancer Commun (Lond); 2018 May; 38(1):29. PubMed ID: 29843800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of recurrence timing and tumor burden score on overall survival among patients undergoing repeat hepatectomy for colorectal liver metastases.
    Endo Y; Rueda BO; Woldesenbet S; Munir MM; Lima HA; Katayama ES; Shaikh CF; Guglielmi A; Ruzzenente A; Aldrighetti L; Alexandrescu S; Kitago M; Poultsides G; Sasaki K; Aucejo F; Pawlik TM
    J Surg Oncol; 2023 Sep; 128(4):560-568. PubMed ID: 37195231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of neoadjuvant chemotherapy with S-1 and oxaliplatin plus bevacizumab for colorectal liver metastasis (N-SOG 05 trial).
    Mukai T; Uehara K; Goto H; Hiramatsu K; Kobayashi S; Sakamoto E; Maeda A; Takeuchi E; Okada Y; Ebata T; Nagino M;
    Jpn J Clin Oncol; 2017 Jul; 47(7):597-603. PubMed ID: 28398493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator.
    Ayez N; van der Stok EP; Grünhagen DJ; Rothbarth J; van Meerten E; Eggermont AM; Verhoef C
    Eur J Surg Oncol; 2015 Jul; 41(7):859-67. PubMed ID: 25979624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Morphological aspects of the hepatic response to neoadjuvant therapy.
    Fernández-Aceñero MJ; Cortés-Guiral D; Muñoz LE; Martínez-Useros J; Pastor-Idoate C
    Pathol Res Pract; 2015 Sep; 211(9):665-70. PubMed ID: 26163186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of neoadjuvant chemotherapy in patients with high-risk resectable colorectal liver metastases.
    Ninomiya M; Emi Y; Motomura T; Tomino T; Iguchi T; Kayashima H; Harada N; Uchiyama H; Nishizaki T; Higashi H; Kuwano H
    Int J Clin Oncol; 2021 Dec; 26(12):2255-2264. PubMed ID: 34519930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Total tumour volume as a prognostic factor in patients with resectable colorectal cancer liver metastases.
    Tai K; Komatsu S; Sofue K; Kido M; Tanaka M; Kuramitsu K; Awazu M; Gon H; Tsugawa D; Yanagimoto H; Toyama H; Murakami S; Murakami T; Fukumoto T
    BJS Open; 2020 Jun; 4(3):456-466. PubMed ID: 32277807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant chemotherapy for borderline resectable colorectal cancer liver metastases: a single-institution retrospective study.
    Kitano Y; Ono Y; Kobayashi K; Oba A; Sato T; Ito H; Inoue Y; Shinozaki E; Yamaguchi K; Saiura A; Baba H; Takahashi Y
    HPB (Oxford); 2024 Feb; 26(2):282-290. PubMed ID: 37985325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.
    Zhou S; Jiang Y; Liang J; Pei W; Zhou Z
    World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatic resection after neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer: need for cautious planning.
    Kim YI; Park IJ; Kim JE; Kim SY; Park JH; Lee JH; Ha TY; Hong YS; Kim SY; Kim TW; Lim SB; Yu CS; Kim JC
    Ann Surg Treat Res; 2019 Nov; 97(5):245-253. PubMed ID: 31742209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Higher Tumor Burden Neutralizes Negative Margin Status in Hepatectomy for Colorectal Cancer Liver Metastasis.
    Oshi M; Margonis GA; Sawada Y; Andreatos N; He J; Kumamoto T; Morioka D; Wolfgang CL; Tanaka K; Weiss MJ; Endo I
    Ann Surg Oncol; 2019 Feb; 26(2):593-603. PubMed ID: 30483976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of Tumor Burden Score for predicting conversion outcome in patients with initially unresectable colorectal liver metastases after first-line systemic therapy.
    Peng J; Liu Y; Li W; Lin Y; Sun H; Pan Z; Wu X; Fan W; Lin J
    Therap Adv Gastroenterol; 2021; 14():17562848211066206. PubMed ID: 34987612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of red blood cell distribution width level on histological response and prognosis in colorectal liver metastases.
    Chen Q; Chen J; Deng Y; Huang Z; Zhao H; Cai J
    Ann Palliat Med; 2021 Sep; 10(9):9383-9397. PubMed ID: 34498473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
    Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
    BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria.
    Tsilimigras DI; Mehta R; Paredes AZ; Moris D; Sahara K; Bagante F; Ratti F; Marques HP; Silva S; Soubrane O; Lam V; Poultsides GA; Popescu I; Grigorie R; Alexandrescu S; Martel G; Workneh A; Guglielmi A; Hugh T; Aldrighetti L; Endo I; Spolverato G; Umberto C; Pawlik TM
    Ann Surg; 2020 Oct; 272(4):574-581. PubMed ID: 32932309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histological tumor response to neoadjuvant chemotherapy correlates to Immunoscore in colorectal cancer liver metastases patients.
    Zhang C; Wang X; Han J; Zhang R; Chen Z; Li Y; Ma X; Zhang G; Fan J; Chen J
    J Surg Oncol; 2021 Dec; 124(8):1431-1441. PubMed ID: 34406653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.